Prestige Biologics Co. Ltd.
Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for… Read more
Prestige Biologics Co. Ltd. (334970) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.051x
Based on the latest financial reports, Prestige Biologics Co. Ltd. (334970) has a cash flow conversion efficiency ratio of 0.051x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩6.21 Billion) by net assets (₩122.27 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Prestige Biologics Co. Ltd. - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Prestige Biologics Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Prestige Biologics Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Prestige Biologics Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alvotech Warrant
NASDAQ:ALVOW
|
0.314x |
|
Daesung Hi-Tech Co. Ltd.
KQ:129920
|
0.020x |
|
Melcor Real Estate Investment Trust
TO:MR-UN
|
0.005x |
|
ABITARE IN S.P.A.
F:1BN
|
N/A |
|
MAGELLANIC CLOUD LTD
NSE:MCLOUD
|
N/A |
|
Enertork Ltd
KQ:019990
|
-0.015x |
|
Bound and Beyond PCL
BK:BEYOND
|
0.068x |
|
Ringmetall SE
XETRA:HP3A
|
0.044x |
Annual Cash Flow Conversion Efficiency for Prestige Biologics Co. Ltd. (2018–2024)
The table below shows the annual cash flow conversion efficiency of Prestige Biologics Co. Ltd. from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩135.20 Billion | ₩-18.31 Billion | -0.135x | -16.31% |
| 2023-12-31 | ₩71.68 Billion | ₩-8.35 Billion | -0.116x | +59.95% |
| 2022-12-31 | ₩117.61 Billion | ₩-34.19 Billion | -0.291x | -20.61% |
| 2021-12-31 | ₩106.83 Billion | ₩-25.75 Billion | -0.241x | -102.52% |
| 2020-12-31 | ₩-1.40 Billion | ₩-13.37 Billion | 9.564x | +2343.77% |
| 2019-12-31 | ₩28.85 Billion | ₩-12.30 Billion | -0.426x | +96.63% |
| 2018-12-31 | ₩822.18 Million | ₩-10.39 Billion | -12.640x | -- |